Meeting
2023 ASCO Annual Meeting
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).
Authors
Aaron Scott Mansfield
Mayo Clinic, Rochester, MN
Aaron Scott Mansfield , Xiaofei F. Wang , Dennis A. Wigle , Colleen Watt , Gregory A. Masters , Kathryn Kelley , David E. Kozono , Tom Stinchcombe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT05647265
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8602)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8602
Abstract #
TPS8602
Poster Bd #
227b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).
First Author: Aaron Scott Mansfield
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer.
First Author: Sakti Chakrabarti
Poster
2020 ASCO Virtual Scientific Program
Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma.
First Author: Joshua E. Reuss
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.
First Author: Michal Sternschuss